(±)-2-(1-amino-2-methylpropyl)-3-benzyl-7-chloroquinazolin-4(3H)-one | 336119-88-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (±)-2-(1-amino-2-methylpropyl)-3-benzyl-7-chloroquinazolin-4(3H)-one
• 英文别名: 2-(1-amino-2-methyl-propyl)-3-benzyl-7-chloro-3H-quinazolin-4-one；2-(1-amino-2-methylpropyl)-3-benzyl-7-chloroquinazolin-4(3H)-one；2-(1-amino-2-methylpropyl)-3-benzyl-7-chloroquinazolin-4-one
• CAS: 336119-88-1
• 化学式: C₁₉H₂₀ClN₃O
• 分子量: 341.84
• InChiKey: OWYDWUOOPZRGNZ-UHFFFAOYSA-N

物化性质

• 沸点：
  510.9±60.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  58.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (±)-2-(1-amino-2-methylpropyl)-3-benzyl-7-chloroquinazolin-4(3H)-one 在 三乙酰氧基硼氢化钠 、 N,N-二异丙基乙胺 、 O,O'-dibenzoyl-L-tartaric acid 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 、 异丙醇 为溶剂， 反应 48.0h， 生成 tert-butyl (3-(N-(1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl)-3-fluorobenzamido)propyl)carbamate
  参考文献：
  名称：

  Fluorinated quinazolinones as potential radiotracers for imaging kinesin spindle protein expression

  摘要：

  Anti-mitotic anti-cancer drugs offer a potential platform for developing new radiotracers for imaging proliferation markers associated with the mitosis-phase of the cell-cycle. One interesting target is kinesin spindle protein (KSP)-an ATP-dependent motor protein that plays a vital role in bipolar spindle formation. In this work we synthesised a range of new fluorinated-quinazolinone compounds based on the structure of the clinical candidate KSP inhibitor, ispinesib, and investigated their properties in vitro as potential anti-mitotic agents targeting KSP expression. Anti-proliferation (MTT and BrdU) assays combined with additional studies including fluorescence-assisted cell sorting (FACS) analysis of cell-cycle arrest confirmed the mechanism and potency of these biphenyl compounds in a range of human cancer cell lines. Additional studies using confocal fluorescence microscopy showed that these compounds induce M-phase arrest via monoaster spindle formation. Structural studies revealed that compound 20-(R) is the most potent fluorinated-quinazolinone inhibitor of KSP and represents a suitable lead candidate for further studies on designing F-18-radiolabelled agents for positron-emission tomography (PET). (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.11.013
• 作为产物：
  描述：

  3-苄基-2-(1-溴-2-甲基丙基)-7-氯喹唑啉-4-酮 在 sodium azide 、 氯化铵 、 锌 作用下， 以 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.5h， 生成 (±)-2-(1-amino-2-methylpropyl)-3-benzyl-7-chloroquinazolin-4(3H)-one
  参考文献：
  名称：

  Fluorinated quinazolinones as potential radiotracers for imaging kinesin spindle protein expression

  摘要：

  Anti-mitotic anti-cancer drugs offer a potential platform for developing new radiotracers for imaging proliferation markers associated with the mitosis-phase of the cell-cycle. One interesting target is kinesin spindle protein (KSP)-an ATP-dependent motor protein that plays a vital role in bipolar spindle formation. In this work we synthesised a range of new fluorinated-quinazolinone compounds based on the structure of the clinical candidate KSP inhibitor, ispinesib, and investigated their properties in vitro as potential anti-mitotic agents targeting KSP expression. Anti-proliferation (MTT and BrdU) assays combined with additional studies including fluorescence-assisted cell sorting (FACS) analysis of cell-cycle arrest confirmed the mechanism and potency of these biphenyl compounds in a range of human cancer cell lines. Additional studies using confocal fluorescence microscopy showed that these compounds induce M-phase arrest via monoaster spindle formation. Structural studies revealed that compound 20-(R) is the most potent fluorinated-quinazolinone inhibitor of KSP and represents a suitable lead candidate for further studies on designing F-18-radiolabelled agents for positron-emission tomography (PET). (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.11.013

文献信息

• [EN] COMPOUNDS, COMPOSITIONS AND METHODS<br/>[FR] COMPOSES, COMPOSITIONS ET METHODES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004055008A1

  公开（公告）日：2004-07-01

  Compounds useful for treating cellular proliferative diseases anddisorders by modulating the activity of KSP are disclosed.

  揭示了通过调节KSP活性治疗细胞增殖性疾病和紊乱的有用化合物。
• Syntheses of quinazolinones
  申请人：——

  公开号：US20040067969A1

  公开（公告）日：2004-04-08

  The present invention provides intermediates, synthetic methods and novel quinazolinone compositions of matter.

  本发明提供了中间体、合成方法和新型喹唑啉酮组合物。
• Compounds, compositions, and methods
  申请人：Feng Bainian

  公开号：US20060094735A1

  公开（公告）日：2006-05-04

  Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

  本发明揭示了通过调节KSP的活性来治疗细胞增殖性疾病和障碍的有用化合物。
• Compounds, compositins, and methods
  申请人：Cytokinetics, Inc.

  公开号：US20040077668A1

  公开（公告）日：2004-04-22

  Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

  本发明揭示了通过调节KSP的活性来治疗细胞增殖性疾病和疾病的有用化合物。
• Compounds, compositions and methods
  申请人：Bergnes Gustave

  公开号：US20060052360A1

  公开（公告）日：2006-03-09

  Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

  本发明揭示了通过调节KSP活性来治疗细胞增殖性疾病和疾病的化合物。